Trial Profile
A Phase II Multi-center, Open-label, Non-randomized Study of Nilotinib as First Line Treatment in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Oct 2019 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Planned End Date changed from 31 Dec 2018 to 1 Aug 2019.
- 01 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2019.